


What is claimed is:

1. A compound of formula (I)



(I)

5 wherein

Ar<sup>1</sup> is selected from benzodioxolyl, pyrrolidinyl,

pyridyl or pyridyl N-oxide, each optionally mono-substituted with C(O)NH<sub>2</sub>, halo, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, amino, hydroxy(C<sub>1</sub>-C<sub>3</sub>)alkyl, or (C<sub>1</sub>-C<sub>3</sub>)alkyl optionally substituted with aminocarbonyl or (C<sub>1</sub>-C<sub>3</sub>)alkylcarbonylamino,

10

a five-membered aromatic heterocycle optionally substituted with 1 or 2 substituents each independently selected from (C<sub>1</sub>-C<sub>3</sub>)alkyl, C(O)H, C(O)(C<sub>1</sub>-C<sub>3</sub>)alkyl, and halo, and

phenyl optionally substituted with 1 or 2 substituents each selected independently from OH, -OCF<sub>3</sub>, CF<sub>3</sub>, CN, halo, NO<sub>2</sub>, NR<sup>5</sup>R<sup>5</sup>, NHC(O)R<sup>6</sup>, NHS(O)<sub>2</sub>R<sup>5</sup>, NHS(O)<sub>2</sub>NR<sup>5</sup>R<sup>5</sup>, S(O)<sub>n</sub>R<sup>8</sup>, C(O)R<sup>10</sup>, C(O)NH(C<sub>1</sub>-C<sub>3</sub>)alkoxy-(C<sub>1</sub>-C<sub>3</sub>)alkyl, C(O)NH(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, pyrrolidinonyl, imidazoliny, imidazolidinonyl, (C<sub>1</sub>-C<sub>3</sub>)alkoxy optionally substituted with 1 or 2 OH groups, and (C<sub>1</sub>-C<sub>3</sub>)alkyl optionally mono-substituted with CN, OH, NR<sup>5</sup>R<sup>5</sup>, NHC(O)R<sup>6</sup>,

15

NHS(O)<sub>2</sub>(C<sub>1</sub>-C<sub>3</sub>)alkyl, C(O)NR<sup>5</sup>R<sup>5</sup>, oxazolidinonyl,

20

imidazolidinonyl optionally mono-substituted with (C<sub>1</sub>-C<sub>3</sub>)alkyl, pyrrolidinonyl optionally mono-substituted with (C<sub>1</sub>-C<sub>3</sub>)alkyl, a five-membered N containing heterocycle optionally mono-substituted with (C<sub>1</sub>-C<sub>3</sub>)alkyl,

piperaziny, optionally mono-substituted with (C<sub>1</sub>-C<sub>3</sub>)alkyl,

25

pyridyl optionally mono-substituted with CF<sub>3</sub>, or (C<sub>1</sub>-C<sub>3</sub>)alkoxy, thienyl optionally mono-substituted with C(O)(C<sub>1</sub>-C<sub>3</sub>)alkyl, or pyrimidinyl optionally mono-substituted with N[(C<sub>1</sub>-C<sub>3</sub>)alkyl]<sub>2</sub>;

Ar<sup>2</sup> is selected from benzodioxolyl,

phenyl optionally substituted with 1 or 2 substituents each selected

30

independently from (C<sub>1</sub>-C<sub>3</sub>)alkyl, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, OH, NO<sub>2</sub>, CN, halo, and CF<sub>3</sub>, and

pyridyl mono-substituted with (C<sub>1</sub>-C<sub>3</sub>)alkyl, or CF<sub>3</sub>;

R<sup>1</sup> is selected from H, (C<sub>1</sub>-C<sub>3</sub>)alkyl, OH, and halo;

$R^2$  is selected from H, (C<sub>1</sub>-C<sub>3</sub>)alkyl, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, OH, halo, CF<sub>3</sub>, and -OCF<sub>3</sub>;

$R^3$  is selected from H, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, OH, halo, and CF<sub>3</sub>;

$R^4$  is selected from hydrogen, (C<sub>1</sub>-C<sub>3</sub>)alkyl, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, CN, and C(O)NHR<sup>5</sup>, wherein (C<sub>1</sub>-C<sub>3</sub>)alkyl can optionally be substituted with halo, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, hydroxyalkylamino, alkoxyalkylamino;

$R^5$  is selected from H, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, and

(C<sub>1</sub>-C<sub>3</sub>)alkyl optionally substituted with 1 or 2 OH groups or

mono-substituted with (C<sub>1</sub>-C<sub>3</sub>)alkoxy, (C<sub>1</sub>-C<sub>3</sub>)alkylamino, S(O)<sub>2</sub>(C<sub>1</sub>-C<sub>3</sub>)alkyl, or C(O)R<sup>7</sup>;

$R^6$  is selected from H, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, CHF<sub>2</sub>, CF<sub>3</sub>, NHR<sup>5</sup>, and (C<sub>1</sub>-C<sub>3</sub>)alkyl optionally substituted with one or more substituents selected from Cl and F, or optionally mono-substituted with NH<sub>2</sub> or NHC(O)(C<sub>1</sub>-C<sub>3</sub>)alkyl;

$R^7$  is selected from (C<sub>1</sub>-C<sub>3</sub>)alkoxy, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, CHF<sub>2</sub>, CF<sub>3</sub>, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, NR<sup>7-1</sup>R<sup>7-1</sup>, and (C<sub>1</sub>-C<sub>3</sub>)alkyl optionally substituted with one or more substituents selected from Cl and F, or mono-substituted with NHC(O)(C<sub>1</sub>-C<sub>3</sub>)alkyl or NH<sub>2</sub>, wherein R<sup>7-1</sup> is hydrogen or (C<sub>1</sub>-C<sub>3</sub>)alkyl;

$R^8$  is selected from (C<sub>1</sub>-C<sub>3</sub>)alkyl and NR<sup>9</sup>R<sup>9</sup>;

$R^9$  is selected from H, and (C<sub>1</sub>-C<sub>3</sub>)alkyl optionally mono-substituted with (C<sub>1</sub>-C<sub>3</sub>)alkoxy, or aminocarbonyl, or substituted with 1 or 2 OH groups;

$R^{10}$  is selected from H, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, NHR<sup>9</sup>, and (C<sub>1</sub>-C<sub>3</sub>)alkyl optionally mono-substituted with pyrrolidinyl, morpholinyl, pyridinyl, piperazinyl optionally substituted with (C<sub>1</sub>-C<sub>3</sub>)alkyl, or piperidinyl optionally substituted with (C<sub>1</sub>-C<sub>3</sub>)alkyl;

n is 0, 1 or 2;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein Ar<sup>1</sup> is

phenyl optionally substituted with 1 or 2 substituents each selected independently from OH, -OCF<sub>3</sub>, CF<sub>3</sub>, CN, halo, NO<sub>2</sub>, NR<sup>5</sup>R<sup>5</sup>, NHC(O)R<sup>6</sup>, NHS(O)<sub>2</sub>R<sup>5</sup>, NHS(O)<sub>2</sub>NR<sup>5</sup>R<sup>5</sup>, S(O)<sub>n</sub>R<sup>8</sup>, C(O)R<sup>10</sup>, C(O)NH(C<sub>1</sub>-C<sub>3</sub>)alkoxy-(C<sub>1</sub>-C<sub>3</sub>)alkyl, C(O)NH(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, pyrrolidinonyl, imidazolinyl, imidazolidinonyl, (C<sub>1</sub>-C<sub>3</sub>)alkoxy optionally substituted with 1 or 2 OH groups, and (C<sub>1</sub>-C<sub>3</sub>)alkyl optionally mono-substituted with CN, OH, NR<sup>5</sup>R<sup>5</sup>, NHC(O)R<sup>6</sup>, NHS(O)<sub>2</sub>(C<sub>1</sub>-C<sub>3</sub>)alkyl, C(O)NR<sup>5</sup>R<sup>5</sup>, oxazolidinonyl,

imidazolidinonyl optionally mono-substituted with (C<sub>1</sub>-C<sub>3</sub>)alkyl,  
 pyrrolidinonyl optionally mono-substituted with (C<sub>1</sub>-C<sub>3</sub>)alkyl,  
 a five-membered N containing heterocycle optionally

mono-substituted with (C<sub>1</sub>-C<sub>3</sub>)alkyl,

piperazinyl optionally mono-substituted with (C<sub>1</sub>-C<sub>3</sub>)alkyl,  
 pyridyl optionally mono-substituted with CF<sub>3</sub>, or (C<sub>1</sub>-C<sub>3</sub>)alkoxy,  
 thienyl optionally mono-substituted with C(O)(C<sub>1</sub>-C<sub>3</sub>)alkyl, or  
 pyrimidinyl optionally mono-substituted with N[(C<sub>1</sub>-C<sub>3</sub>)alkyl]<sub>2</sub>,

R<sup>5</sup> is selected from H, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, and

(C<sub>1</sub>-C<sub>3</sub>)alkyl optionally substituted with 1 or 2 OH groups or

mono-substituted with (C<sub>1</sub>-C<sub>3</sub>)alkoxy, (C<sub>1</sub>-C<sub>3</sub>)alkylamino, S(O)<sub>2</sub>(C<sub>1</sub>-C<sub>3</sub>)alkyl,  
 or C(O)R<sup>7</sup>;

R<sup>6</sup> is selected from H, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, CHF<sub>2</sub>, CF<sub>3</sub>, NHR<sup>5</sup>,  
 and (C<sub>1</sub>-C<sub>3</sub>)alkyl optionally substituted with one or more substituents selected from  
 Cl and F, or optionally mono-substituted with NH<sub>2</sub> or NHC(O)(C<sub>1</sub>-C<sub>3</sub>)alkyl;

R<sup>7</sup> is selected from (C<sub>1</sub>-C<sub>3</sub>)alkoxy, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, CHF<sub>2</sub>, CF<sub>3</sub>, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, NR<sup>7-1</sup>R<sup>7-1</sup>,  
 and (C<sub>1</sub>-C<sub>3</sub>)alkyl optionally substituted with one or more substituents selected from  
 Cl and F, or mono-substituted with NHC(O)(C<sub>1</sub>-C<sub>3</sub>)alkyl or NH<sub>2</sub>,

wherein R<sup>7-1</sup> is hydrogen, methyl or ethyl;

R<sup>8</sup> is selected from (C<sub>1</sub>-C<sub>3</sub>)alkyl and NR<sup>9</sup>R<sup>9</sup>;

R<sup>9</sup> is selected from H, and (C<sub>1</sub>-C<sub>3</sub>)alkyl optionally mono-substituted with  
 (C<sub>1</sub>-C<sub>3</sub>)alkoxy, or aminocarbonyl, or substituted with 1 or 2 OH groups;

R<sup>10</sup> is selected from H, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, NHR<sup>9</sup>, and


(C<sub>1</sub>-C<sub>3</sub>)alkyl optionally mono-substituted with pyrrolidinyl, morpholinyl, pyridinyl,  
 piperazinyl optionally substituted with (C<sub>1</sub>-C<sub>3</sub>)alkyl, or  
 piperidinyl optionally substituted with (C<sub>1</sub>-C<sub>3</sub>)alkyl;

3. The compound of claim 1, wherein Ar<sup>2</sup> is 2,4-dihalosubstituted phenyl.

4. The compound of claim 1, wherein Ar<sup>2</sup> is 2,4-dichlorophenyl.

5. The compound of claim 1, wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are hydrogen.

6. A process for preparing a compound of Claim 1, wherein a compound of formula  
 (X)




wherein  $R^1$  to  $R^4$  and  $Ar^2$  have the meaning indicated in claim 1,

is reacted with a compound (IV)

5



wherein  $Ar^1$  has the meaning indicated in claim 1, and where  $R'$  is selected in each instance independently from H and  $(C_1-C_3)$ alkyl, or (IV) represents



10

in the presence of a palladium catalyst and base.

15

7. The compound of claim 1 for the treatment and/or prophylaxis of disorders.

8. A pharmaceutical composition comprising a compound according to claim 1.

20

9. A pharmaceutical composition comprising a compound according to claim 1 in combination with at least one pharmaceutically acceptable excipient.

25

10. A process for preparing the pharmaceutical composition of claim 9, comprising combining at least one compound of claim 1 with at least one pharmaceutically acceptable excipient, mixing the combination and bringing the combination into a suitable administration form.

11. The pharmaceutical composition of claim 8 for the treatment or prophylaxis of hyperproliferative disorders.

12. The use of a compound according to claim 1 for manufacturing a medicament for the treatment or prophylaxis of hyperproliferative disorders.

13. A method of treating a disease or condition in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound according to the formula (I).

14. The method of claim 13, wherein the disease or condition is a hyperproliferative disorder.